Hyderabad, June 8: Viyash Scientific Ltd, formerly known as Sequent Scientific, on Monday said its step-down wholly-owned subsidiary, Alivira Animal Health Ltd, Ireland, has entered into a binding agreement to acquire Italian veterinary products company BioForLife Italia S.r.l. for an aggregate consideration of €16.975 million.
The acquisition, which will be carried out through cash consideration, includes an upfront payment of €15 million at closing and deferred consideration of €1.975 million, payable in accordance with the terms of the transaction documents.
According to a regulatory filing, the transaction is aimed at strengthening Viyash Scientific’s presence in the companion animal healthcare segment in Italy by providing access to an established distribution platform, customer network and product portfolio.
BioForLife Italia, based in Milan, is engaged in the marketing and distribution of veterinary products for companion animals, including medicines, nutraceuticals and diagnostic testing kits. The company generated sales of approximately €9 million in calendar year 2025, compared with €8.3 million in 2024 and €7.1 million in 2023.
The acquisition is subject to customary closing conditions and regulatory approvals, including notification requirements under Italy’s Golden Power laws. The initial closing is expected within three months from the execution of the binding agreement, while the deferred consideration, if applicable, will be settled within 12 months of completion.
Viyash Scientific said the transaction does not constitute a related-party transaction and that neither the promoter group nor group companies have any interest in the target entity.
Founded in 2010, BioForLife derives the bulk of its revenue from the Italian market and focuses on products catering to the companion animal segment. The acquisition is expected to bolster Alivira Animal Health’s front-end capabilities and expand its footprint in one of Europe’s key veterinary healthcare markets.
The deal marks another step in Viyash Scientific’s strategy of strengthening its global animal health business through targeted acquisitions and expanding its presence in high-growth companion animal markets.